Suppr超能文献

细胞因子疗法联合纳米材料参与癌症免疫治疗。

Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy.

作者信息

Lian Heping, Ma Shuang, Zhao Duoyi, Zhao Wei, Cui Yan, Hua Yingqi, Zhang Zhiyu

机构信息

Department of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.

Nursing Department, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.

出版信息

Pharmaceutics. 2022 Nov 26;14(12):2606. doi: 10.3390/pharmaceutics14122606.

Abstract

Immunotherapy has gradually become an emerging treatment modality for tumors after surgery, radiotherapy, and chemotherapy. Cytokine therapy is a promising treatment for cancer immunotherapy. Currently, there are many preclinical theoretical bases to support this treatment strategy and a variety of cytokines in clinical trials. When cytokines were applied to tumor immunotherapy, it was found that the efficacy was not satisfactory. As research on tumor immunity has deepened, the role of cytokines in the tumor microenvironment has been further explored. Meanwhile, the study of nanomaterials in drug delivery has been fully developed in the past 20 years. Researchers have begun to think about the possibility of combining cytokine therapy with nanomaterials. Herein, we briefly review various nano-delivery systems that can directly deliver cytokines or regulate the expression of cytokines in tumor cells for cancer immunotherapy. We further discussed the feasibility of the combination of various therapies. We looked forward to the main challenges, opportunities, and prospects of tumor immunotherapy with multiple cytokines and a nano-delivery system.

摘要

免疫疗法在手术、放疗和化疗之后已逐渐成为一种新兴的肿瘤治疗方式。细胞因子疗法是癌症免疫治疗中一种很有前景的治疗方法。目前,有许多临床前理论基础支持这种治疗策略,并且有多种细胞因子正处于临床试验阶段。当细胞因子应用于肿瘤免疫治疗时,发现疗效并不令人满意。随着对肿瘤免疫研究的深入,细胞因子在肿瘤微环境中的作用得到了进一步探索。与此同时,纳米材料在药物递送方面的研究在过去20年中得到了充分发展。研究人员开始思考将细胞因子疗法与纳米材料相结合的可能性。在此,我们简要综述了各种可直接递送细胞因子或调节肿瘤细胞中细胞因子表达以用于癌症免疫治疗的纳米递送系统。我们进一步讨论了各种疗法联合使用的可行性。我们展望了多种细胞因子与纳米递送系统用于肿瘤免疫治疗面临的主要挑战、机遇和前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/caad/9788370/43c12d116cf1/pharmaceutics-14-02606-sch001.jpg

相似文献

1
Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy.
Pharmaceutics. 2022 Nov 26;14(12):2606. doi: 10.3390/pharmaceutics14122606.
2
Nanodrug Delivery Systems in Antitumor Immunotherapy.
Biomater Res. 2024 Apr 25;28:0015. doi: 10.34133/bmr.0015. eCollection 2024.
3
Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy.
Int J Nanomedicine. 2022 Oct 3;17:4677-4696. doi: 10.2147/IJN.S376216. eCollection 2022.
4
Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
Acta Biomater. 2021 Apr 15;125:1-28. doi: 10.1016/j.actbio.2021.02.030. Epub 2021 Feb 24.
6
Nanomaterials in tumor immunotherapy: new strategies and challenges.
Mol Cancer. 2023 Jun 13;22(1):94. doi: 10.1186/s12943-023-01797-9.
7
Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jul;12(4):e1612. doi: 10.1002/wnan.1612. Epub 2020 Mar 1.
8
Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy.
AAPS J. 2019 May 17;21(4):64. doi: 10.1208/s12248-019-0333-y.
9
Nanomaterials: Breaking through the bottleneck of tumor immunotherapy.
Int J Biol Macromol. 2023 Mar 1;230:123159. doi: 10.1016/j.ijbiomac.2023.123159. Epub 2023 Jan 5.
10
Recent Advance of Nanomaterial-Mediated Tumor Therapies in the Past Five Years.
Front Pharmacol. 2022 Feb 18;13:846715. doi: 10.3389/fphar.2022.846715. eCollection 2022.

引用本文的文献

1
Nanocarriers for cutting-edge cancer immunotherapies.
J Transl Med. 2025 Apr 16;23(1):447. doi: 10.1186/s12967-025-06435-0.
2
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.
Mol Cancer. 2025 Jan 18;24(1):26. doi: 10.1186/s12943-024-02214-5.
3
CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad.
Int J Mol Sci. 2024 Dec 7;25(23):13157. doi: 10.3390/ijms252313157.
4
Nanomedicine for cancer patient-centered care.
MedComm (2020). 2024 Oct 20;5(11):e767. doi: 10.1002/mco2.767. eCollection 2024 Nov.

本文引用的文献

2
3
pH-Responsive Nanoparticles for Multidimensional Combined Chemo-Immunotherapy of Cancer.
J Pharm Sci. 2022 Aug;111(8):2353-2368. doi: 10.1016/j.xphs.2022.05.008. Epub 2022 May 15.
4
In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4 and CD8 T-cell epitopes for cancer immunotherapy.
Cancer Immunol Immunother. 2022 Dec;71(12):2969-2983. doi: 10.1007/s00262-022-03209-1. Epub 2022 May 12.
5
Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy.
J Control Release. 2022 May;345:306-313. doi: 10.1016/j.jconrel.2022.03.021. Epub 2022 Mar 14.
6
Harnessing cytokines and chemokines for cancer therapy.
Nat Rev Clin Oncol. 2022 Apr;19(4):237-253. doi: 10.1038/s41571-021-00588-9. Epub 2022 Jan 7.
8
Overcoming T Cell Exhaustion via Immune Checkpoint Modulation with a Dendrimer-Based Hybrid Nanocomplex.
Adv Healthc Mater. 2021 Oct;10(19):e2100833. doi: 10.1002/adhm.202100833. Epub 2021 Jul 1.
10
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy.
Nanomicro Lett. 2020 Jul 5;12(1):142. doi: 10.1007/s40820-020-00482-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验